How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

746 results for


Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Pharmacotherapy for overweight/obesity in ethnic minorities and White Caucasians: a systematic review and meta-analysis

pharmacotherapy for comparisons of ethnic groups. The data appeared to show positive weight management results with orlistat and sibutramine; weight loss with sibutramine was significantly lower in ethnic minorities versus Caucasians. The review was generally well conducted. The authors’ conclusions were suitably cautious and appear appropriate. Authors' objectives To compare the effectiveness of anti-obesity medications in ethnic minorities and white Caucasians. Searching MEDLINE, EMBASE, The Cochrane (...) Library, CINAHL, DARE and Current Controlled Trials were searched from January 1990 to June 2010 for articles in English. Search terms were reported. Reference lists of identified trials were searched. Study selection Randomised controlled trials (RCTs) of orlistat or sibutramine versus placebo in white and ethnic minority adult participants (aged 18 years and over) that evaluated changes in weight or body mass index (BMI) and at least one secondary outcome (waist circumference, fasting lipid

2012 DARE.

102. Cost-effectiveness of pharmacotherapy to reduce obesity

Study objective This study evaluated the cost-effectiveness of pharmaceutical interventions, versus standard care, for obesity in Australian adults aged 20 years or older. Interventions Pharmaceutical care consisted of either 15mg sibutramine, once daily, or 120mg of orlistat, thrice daily. Patients were allowed one 12-month course of treatment. This was compared with usual care, with no drug treatment. Location/setting Australia/primary care. Methods Analytical approach: The authors used a Markov (...) not take their medication. Weight regain data were from the Sibutramine Trial of Obesity Reduction and Maintenance (STORM) trial for sibutramine and were assumed to be the same for orlistat. It was assumed that none of the weight loss was permanent. Monetary benefit and utility valuations: Health-related quality of life utilities were calculated, for the nine disease states, using disability-adjusted life-year (DALY) weights from an Australian study. Measure of benefit: The DALYs averted were

Full Text available with Trip Pro

2011 NHS Economic Evaluation Database.

103. Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis

: sulfonylureas, meglitinides, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 analogues, insulins and insulin analogues, alpha-glucosidase inhibitors, and weight-loss agents (orlistat and sibutramine). Outcomes of interest included glycated haemoglobin (HbA 1c ), hypoglycaemia, body weight, quality of life, long-term complications of diabetes, severe adverse events, and mortality. In included trials, the mean baseline glycated haemoglobin ranged from 6.6% to 10

2011 DARE.

104. Clinical Trial for PB-119 in Subjects With Type 2 Diabetes Mellitus

(such as orlistat, sibutramine, rimonabant, phenylpropanol or chlorpheniramine) that promote weight loss within 3 months before study; Take any medications that may affect test results, such as antibiotics, non-steroidal anti-inflammatory drugs, antacids containing aluminum or magnesium, diuretics, anticoagulants, central nervous system inhibitors, systemic corticosteroids, medications to slow down the gastrointestinal motility, and any drug that may possibly affect the absorption of the drug within 2 weeks

2017 Clinical Trials

105. Targeted Enteral Nutrient Delivery: A Prospective Randomized Study

, and lithium) thioridazine, clozapine, Currently using or have used within three months prior to screening for this trial: pramlintide, sibutramine, orlistat, zonisamide, topiramate or phenteremine (either by prescription or as part of a clinical trial) Simultaneous participation in any other clinical trial of an investigational drug The receipt of any investigational product within four weeks prior to screening for this trial Herbal supplements or over-the-counter medications Diet attempts using herbal

2017 Clinical Trials

106. Treatment of Pediatric Obesity: An Umbrella Systematic Review. (PubMed)

circumference, BMI, and diastolic blood pressure (low quality of evidence). Pharmacological interventions reduced BMI (metformin, sibutramine, orlistat) and waist circumference (sibutramine, orlistat) and increased high-density lipoprotein cholesterol (sibutramine) but also raised systolic and diastolic blood pressure (sibutramine). Surgical interventions (laparoscopic adjustable gastric banding, Roux-en-Y gastric bypass, sleeve gastrectomy) resulted in the largest BMI reduction (moderate quality

Full Text available with Trip Pro

2017 The Journal of clinical endocrinology and metabolism

107. Testing the usefulness of the number needed to treat to be harmed (NNTH) in benefit-risk evaluations: case study with medicines withdrawn from the European market due to safety reasons.

]), new-onset diabetes (113[NS] vs. 390[425-778]), bleeding (∞ vs. 517[317-1153]), and infection (∞ vs. 253[164-463]) with niacin-laropiprant; psychiatric disorders (12[7-34] vs. 9[5-24]) with rimonabant; myocardial infarction (MI) [-1305 vs. 270[89-4362]) with rofecoxib; MI (-510 vs. NNTH ranging from 152[55-4003] to 568[344-1350]) with rosiglitazone; cardiovascular events (∞ vs. 245[129-1318]) with sibutramine; and liver injury (∞ vs. 5957[NS]) with ximelagatran.NNTH have potential of use

2017 Expert opinion on drug safety

108. Effect of Combined Morphine and Duloxetine on Chronic Pain

, lithium, linezolid, tramadol (Ultram), St. John's Wort, central nervous system (CNS) stimulants such as amphetamine, methylphenidate, methamphetamine, phentermine, diethylpropion, sibutramine, cocaine, or thioridazine. Subject has uncontrolled narrow-angle glaucoma. Subject has sensory deficits on arms or Raynaud's Syndrome. Subject has a pending litigation related to chronic pain condition. Subject is on methadone or suboxone treatment for addiction. Contacts and Locations Go to Information from

2017 Clinical Trials

109. Effects of Cinnamon Supplementation on Glucose Metabolism in Patients With Pre-diabetes

or hypersensitivity to any of the ingredients in the test products. Cognitive impairment or any other reason to expect the patient would have difficulty complying with study protocol Excessive alcohol intake defined as greater than 3 units of alcohol per day. Use of weight loss drugs (e.g., lorcaserin [Belviq]; phentermine/topiramate [Qsymia], liraglutide [Saxenda], Xenical [orlistat], Meridia [sibutramine], Acutrim [phenylpropanol-amine], or similar over-the-counter medications) within 3 months of the screening

2017 Clinical Trials

110. Ultrasound Assessment of the Adventitia, Extra-media (EMT) and Veia Jugularis Interna Thickness

, or participation within the last 3 months, in an organised weight loss programme (or within the last 3 months) Current or history of treatment with medications that may cause significant weight gain for at least 3 months before this trial Current use or use within three months before this trial of GLP-1 receptor agonist, pramlintide, sibutramine, orlistat, zonisamide, topiramate, or phentermine Type 1 diabetes Type 2 diabetes treated with glucose-lowering drugs other than metformin Alloplasty in target knee

2017 Clinical Trials

111. A Phase IV Study in Drug-Naive Patients With T2DM in China

affect the interpretation of efficacy or safety data. History of bone fracture secondary to diagnosed severe osteoporosis. Currently unstable or serious cardiovascular, renal, hepatic, hematologic, oncologic, endocrine, psychiatric, or rheumatic diseases as judged by the Investigator. Replacement or chronic systemic corticosteroid therapy, defined as any dose of systemic corticosteroid taken for >4 weeks within 3 months before enrollment visit. Administration of sibutramine, phentermine, orlistat

2017 Clinical Trials

112. Effect of Resistant Starch on Insulin Sensitivity and Beta Cell Function in Subjects With Prediabetes

, the administration of a treatment that may affect the interpretation of the efficacy and safety data. Treatment with any oral antidiabetic medicinal product and / or herbal preparations / non-prescription medicines that may affect glycemic control within 12 weeks prior to screening. Chronic treatment with oral or parenteral corticosteroids (> 7 consecutive days of treatment) within 4 weeks prior to screening. Treatment with weight-reducing agents (eg, orlistat, sibutramine, topiramate, bupropion) within the last

2017 Clinical Trials

113. Celecoxib Window of Opportunity Trial to Assess Tumor and Stroma Responses

requirements for chemotherapy, radiotherapy or hormonal therapy. Participants must be willing to discontinue any use of NSAIDs like aspirin or ibuprofen until the tumor is removed Participants cannot be taking the following medications because of major pharmacokinetic interactions with celecoxib while being enrolled in the study: Abciximab, Argatroban, Bivalirudin, Cilostazol, Dabigatran, Etexilate, Dipyridamole, Fondaparinux, Heparin, Lepirudin, Pemetrexed, Protein C, Rivaroxaban, Sibutramine, Ticlopidine

2017 Clinical Trials

114. Anxiety-mediated Impairments in Large Elastic Artery Function and the Autonomic Nervous System

populations (prisoners, etc.) will not be eligible to participate in this study. On weight loss drugs (i.e. orilistat (Xenical®), sibutramine (Meridia®), phenylpropanol-amine (Acutrim®)), or similar over-the-counter medications within 3 months of screening. Any surgery within 30 days of screening Those who currently donate blood, platelets, or plasma Any condition that, in the view of the PI or Co-I, places the subject at high risk or poor treatment and study compliance. We will also enroll 36 (...) ). Taking steroids or biologics: corticosteroids (prednisone); methotrexate, infliximib (Remicade®), etaneracept (Enbrel®); anakinra (Kineret®). Those who are currently donating blood, platelets, or plasma at the time of screening. Vulnerable populations (prisoners, etc.) will not be eligible to participate in this study. On weight loss drugs (i.e. orilistat (Xenical®), sibutramine (Meridia®), phenylpropanol-amine (Acutrim®)), or similar over-the-counter medications within 3 months of screening. Any

2017 Clinical Trials

115. Dose Escalation Trial of Single Subcutaneous Doses of NNC 0113-0217 to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Subjects

of the study Use of weight lowering medications (orlistat, sibutramine, rimonabant, phentermine) Clinically significant GI (Gastro-Intestinal) disease including inflammatory bowel disease, irritable bowel syndrome, celiac disease, dyspepsia, apparent diabetic gastro paresis, diabetic diarrhoea, or surgery of the gastro-intestinal tract (except appendectomy and cholecystectomy) Subjects who are sexually active and have not been surgically sterilised must be informed that they and their partner use a highly

2017 Clinical Trials

116. Fluorescent Imaging & Methylene Blue: Ureter Study

: Patient who is unable or unwilling to give informed consent Female participant who is pregnant, lactating or planning pregnancy during the course of the trial. Significant renal or hepatic impairment. Any patients with previous allergies to Methylene Blue Any patients at risk of serotonin syndrome, including those taking serotonin reuptake inhibitors (SSRIs) or serotonin reuptake inhibitors (e.g. duloxetine, sibutramine, venlafaxine, clomipramine, imipramine) Patients with glucose-6-phosphate

2017 Clinical Trials

117. J K Aronson – The Hitchhiker’s Guide to Clinical Pharmacology Part 2

Withdrawn Torcetrapib 2006 Cardiotoxicity Withdrawn Sibutramine 2010 Cardiotoxicity Withdrawn Rosiglitazone 2011 Cardiotoxicity Withdrawn Occasionally a drug may be withdrawn but then reintroduced for specific reasons or with specific monitoring. Examples include: clozapine, a dopamine D 2 receptor antagonist used to treat schizophrenia, which was withdrawn in 1985 because of neutropenia, but was then reintroduced in 1989 with a mandatory blood monitoring scheme, in order to detect neutropenia as soon

2016 CEBM blog

118. Ferulic acid lowers body weight and visceral fat accumulation via modulation of enzymatic, hormonal and inflammatory changes in a mouse model of high-fat diet-induced obesity (PubMed)

male Swiss mice, weighing 20-25 g (n=6-8 per group) were fed a normal diet (ND) or HFD, treated orally or not with either FA (10 mg/kg) or sibutramine (10 mg/kg) for 15 weeks and at the end of this period, the body weights of animals, visceral fat accumulation, plasma levels of glucose and insulin hormone, amylase and lipase activities, the satiety hormones ghrelin and leptin, and tumor necrosis factor-α (TNF-α) and monocyte chemoattractant protein-1 (MCH-1) were analyzed. Results revealed that FA (...) could effectively suppress the HFD-associated increase in visceral fat accumulation, adipocyte size and body weight gain, similar to sibutramine, the positive control. FA also significantly (P<0.05) decreased the HFD-induced elevations in serum lipid profiles, amylase and lipase activities, and the levels of blood glucose and insulin hormone. The markedly elevated leptin and decreased ghrelin levels seen in HFD-fed control mice were significantly (P<0.05) reversed by FA treatment, almost reaching

Full Text available with Trip Pro

2017 Brazilian Journal of Medical and Biological Research

119. Exogenous T3 toxicosis following consumption of a contaminated weight loss supplement (PubMed)

a weight loss product online from India which supposedly contained sibutramine. He provided one of the tablets and laboratory analysis confirmed the presence of T3 in the tablet. Full symptomatic resolution and normalised thyroid function ensued upon discontinuation of the supplement.Free tri-iodothyronine (T3) measurement may be useful in the presence of symptoms suggestive of thyrotoxicosis with discordant thyroid function tests.Thyroid uptake scanning can be a useful aid to differentiating exogenous

Full Text available with Trip Pro

2017 Endocrinology, diabetes & metabolism case reports

120. A systematic review and mixed treatment comparison of pharmacological interventions for the treatment of obesity.

A systematic review and mixed treatment comparison of pharmacological interventions for the treatment of obesity. The study aims to compare anti-obesity interventions in a single evidence synthesis framework. Electronic databases were searched for randomized controlled trials of orlistat, rimonabant or sibutramine reporting weight or body mass index (BMI) change from baseline at 3, 6 or 12 months. A mixed treatment comparison was used to combine direct and indirect trial evidence. Ninety-four (...) studies involving 24,808 individuals were included; 83 trials included data on weight change and 41 on BMI change. All results are in comparison with placebo. The active drugs were all effective at reducing weight and BMI. At 3 months, orlistat reduced weight by -2.65 kg (95% credibility interval -4.00 kg, -1.31 kg). For sibutramine, 15 mg gave a greater reduction than 10 mg at 12 months, -6.35 kg versus -5.42 kg, respectively. Rimonabant reduced weight by -11.23 kg at 3 months and -4.55 kg at 12

2017 Obesity reviews : an official journal of the International Association for the Study of Obesity

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>